Does Rallies show 13F holders for JNJ?

Yes. Rallies tracks hedge fund and 13F ownership data for JNJ, including fund names, share counts, latest tracked quarter, and position changes when available.

Is JNJ research on Rallies investment advice?

No. Rallies provides research, data, and educational context for JNJ. It does not provide personalized investment advice.

JNJ (Johnson & Johnson) Stock Analysis - Hedge Fund Holdings

Johnson & Johnson (JNJ) is a publicly traded Healthcare sector company. As of May 20, 2026, JNJ trades at $230.25 with a market cap of $551.06B and a P/E ratio of 26.42. JNJ moved -0.35% today. Year to date, JNJ is +10.92%; over the trailing twelve months it is +50.83%. Its 52-week range spans $140.68 to $251.71. Analyst consensus is buy with an average price target of $264.75. Rallies surfaces JNJ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns JNJ stock?

Hedge funds tracked by Rallies that own JNJ include GQG Partners, Panagora Asset, Bridgewater Associates, Pinebridge Investments, and Berkshire Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Johnson & Johnson.

JNJ Key Metrics

Key financial metrics for JNJ
Metric	Value
Price	$230.25
Market Cap	$551.06B
P/E Ratio	26.42
EPS	$8.73
Dividend Yield	1.34%
52-Week High	$251.71
52-Week Low	$140.68
Volume	3.37M
Avg Volume	0
Revenue (TTM)	$96.36B
Net Income	$21.04B
Gross Margin	67.82%

Top Hedge Funds Holding JNJ

GQG Partners holds 7.32M shares of JNJ, changed -5.61% as of Mar 31, 2026.
Panagora Asset holds 777.78K shares of JNJ, changed +8.97% as of Mar 31, 2026.
Bridgewater Associates holds 696.88K shares of JNJ, changed -46.96% as of Mar 31, 2026.
Pinebridge Investments holds 295.92K shares of JNJ, changed -21.59% as of Sep 30, 2025.
Berkshire Asset holds 249.74K shares of JNJ, changed -0.56% as of Mar 31, 2026.

Latest JNJ News

Johnson & Johnson Reports Darzalex, Tremfya Growth with AAA Rating, 64-Year Dividend Streak — May 19, 2026
Nanoradioenhancer JNJ-1900 Posts 85.7% Response Rate; Ebola Emergency Declared — May 17, 2026
Johnson & Johnson Stock Falls 3.5% as Survey Finds Over 90% of Bladder Cancer Patients Report Severe Impacts — May 14, 2026
JNJ jumps as Leerink upgrades to Outperform and lifts target to $265 — May 13, 2026
Johnson & Johnson Secures AAA Rating, One of Only Two U.S. Firms — May 13, 2026

Recent JNJ Insider Trades

Decker Robert J sold 4.08K (~$1.01M) on Feb 27, 2026.
Schmid Timothy sold 1.32K (~$324.76K) on Feb 20, 2026.
Schmid Timothy sold 13.63K (~$3.33M) on Feb 18, 2026.

JNJ Analyst Consensus

18 analysts cover JNJ: 0 strong buy, 12 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $264.75.

Common questions about JNJ

Who owns JNJ stock?: Hedge funds tracked by Rallies that own JNJ include GQG Partners, Panagora Asset, Bridgewater Associates, Pinebridge Investments, and Berkshire Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Johnson & Johnson.
Does Rallies show 13F holders for JNJ?: Yes. Rallies tracks hedge fund and 13F ownership data for JNJ, including fund names, share counts, latest tracked quarter, and position changes when available.
Is JNJ research on Rallies investment advice?: No. Rallies provides research, data, and educational context for JNJ. It does not provide personalized investment advice.